Trial Profile
A Phase 2 Study Evaluating Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Carmustine (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Etoposide (Primary) ; Tucidinostat (Primary)
- Indications Diffuse large B cell lymphoma; Lymphoma; Mantle-cell lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 30 Dec 2021 Planned End Date changed from 1 Aug 2020 to 31 Dec 2021.
- 30 Dec 2021 Planned primary completion date changed from 1 Aug 2019 to 31 Dec 2021.
- 30 Dec 2021 Status changed from recruiting to active, no longer recruiting.